NTECライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 1月 1970 @ 09:00):

Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel...

Stats
本日の出来高	988 303
平均出来高	1.05M
時価総額	0.00
EPS	$0 ( 2021-08-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.345 (3.58%)

Insider Trading

Date	Person	Action	Amount	type
2021-07-23	Hayes William B	Sell	250	Stock Option (right to buy)
2021-07-23	Hayes William B	Sell	250	Stock Option (right to buy)
2021-07-23	Hayes William B	Sell	500	Stock Option (right to buy)
2021-07-23	Karah Hila	Sell	281	Stock Option (right to buy)
2021-07-23	Karah Hila	Sell	250	Stock Option (right to buy)

INSIDER POWER
0.00
Last 59 transactions
Buy: 3 599 185 \| Sell: 7 817 315

ボリューム相関

長: 0.44 (neutral)

短: 0.85 (strong)

Signal:(64.456) Same movement expected

Intec Pharma Ltd 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Intec Pharma Ltd 相関 - 通貨/商品

0.42
( neutral )

0.46
( neutral )

-0.20
( neutral )

0.28
( neutral )

-0.59
( weak negative )

-0.32
( neutral )

Intec Pharma Ltd 財務諸表

Annual	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-14.30

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-14.30

FY	2019
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-112.74

FY	2018
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-111.67

Financial Reports:

No articles found.

Intec Pharma Ltd

Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd in March 2004. Intec Pharma Ltd was founded in 2000 and is based in Jerusalem, Israel.